Cipla Ltd — Q3 FY25
Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% US...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY25
Lanreotide supply issues to resolve by end of Q3, recovery in Q4
Supply challenges expected to be resolved by end of Q3, with sharp recovery in lanreotide franchise from Q4 FY25.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1